CinPhloro Pharma, A CinRx Portfolio Company, Dosed First Participant in Phase 2 enviva Study of CIN-103 for IBS-D
![Cinphloro clinical trial IBS-D](https://cinrx.com/wp-content/uploads/2024/02/web-tile-500x200-cinphloro-1.png)
CinPhloro Pharma Dosed First Participant in Phase 2 enviva Study of CIN-103 for IBS-D.
CinFina Pharma, a CinRx Portfolio Company, Introduces Scientific Advisory Board with Deep Metabolic Expertise
![](https://cinrx.com/wp-content/uploads/2022/09/cinfina-tile.jpg)
CinFina Pharma, a CinRx Portfolio Company, Introduces Scientific Advisory Board with Deep Metabolic Expertise.
CinRx Portfolio Company CinDome Pharma Presents Encouraging Data on Deudomperidone (CIN-102) at 2023 Digestive Disease Week® Conference
![](https://cinrx.com/wp-content/uploads/2023/05/cinrx-portfolio-company-cindome-pharma-presents-encouraging-data-on-deudomperidone-cin-102-at-2023-digestive-disease-week-conference-1.jpg)
CinDome Pharma, a CinRx portfolio company, presented a poster at the 2023 Digestive Disease Week (DDW) Conference.